Diffuse erythematous rash after teneligliptin therapy: A case report.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 30613561.
- Also identified by DOI 10.4103/jfmpc.jfmpc_283_18 and PMC identifier 6293926.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We report a yet unreported, adverse effect of teneligliptin [Dipeptidyl peptidase IV inhibitor (DPP IV)] presenting as diffuse pruritic erythematous rash, in a patient, 2 days after initiation of the drug. The rash waned off after the discontinuation of the drug without any residual lesion.